Exploratory analysis of HSPCs from study patients
MUTANT
An exploratory analysis was undertaken to investigate the differences between responders and non-responders. Changes in mutant allele burden were paralleled by the in vitro response of HSPCs from study patients to the soluble metabolite of tamoxifen (4-hydroxytamoxifen, 4OH-TAM). Colony-forming units in culture (CFU-Cs) from the available baseline peripheral blood samples were reduced after 24 h treatment with 4OH-TAM in tamoxifen-responders only (Fig. 